14 October 2021  
EMA/578657/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Zeposia 
ozanimod 
On 14 October 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Zeposia. The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb Pharma 
EEIG. 
The CHMP adopted an extension to the existing indication as follows:2 
Multiple sclerosis  
Zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) 
with active disease as defined by clinical or imaging features. 
Ulcerative colitisZeposia is indicated for the treatment of adult patients with moderately to 
severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or 
were intolerant to either conventional therapy or a biologic agent. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
